IN BRIEF
TRENTON, N.J. — Outside advisers to the Food and Drug Administration voted Thursday to recommend that the agency approve a new anticlotting drug for use in millions more patients.
Johnson & Johnson and partner Bayer Healthcare of Germany, which jointly developed the drug, Xarelto, are seeking U.S. approval for preventing strokes in patients with a common irregular heart rhythm.
